Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 14/20 | 0.47 |
| ▸ | HPGDS | O60760 | 1/20 | 0.46 |
| ▸ | CDC7 | O00311 | 1/20 | 0.44 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.44 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.44 |
| ▸ | KIT | P10721 | 1/20 | 0.44 |
| ▸ | AKT2 | P31751 | 1/20 | 0.44 |
| ▸ | GSK3B | P49841 | 1/20 | 0.44 |
| ▸ | JAK1 | P23458 | 5/20 | 0.43 |
| ▸ | JAK2 | O60674 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3535805 | 0.78 | JAK3 (0.57) | JAK3HPGDSCDC7DBF4NOTUM | |
| SCHEMBL1444375 | 0.69 | JAK1 (0.33) | JAK1JAK2 | |
| SCHEMBL8929274 | 0.69 | CDC7 (0.46) | JAK3HPGDSCDC7DBF4NOTUM | |
| SCHEMBL24121893 | 0.67 | JAK3 (0.49) | JAK3HPGDSJAK1JAK2 | |
| SCHEMBL10169662 | 0.66 | JAK3 (0.67) | JAK3KITAKT2GSK3BJAK1 | |
| SCHEMBL20582811 | 0.66 | JAK3 (0.67) | JAK3KITAKT2GSK3BJAK1 | |
| SCHEMBL10169663 | 0.66 | JAK3 (0.67) | JAK3KITAKT2GSK3BJAK1 | |
| SCHEMBL10170240 | 0.66 | JAK3 (0.67) | JAK3KITAKT2GSK3BJAK1 | |
| SCHEMBL15208683 | 0.66 | JAK3 (0.67) | JAK3KITAKT2GSK3BJAK1 | |
| SCHEMBL2113254 | 0.65 | HPGDS (0.58) | JAK3HPGDSJAK1JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170037059-A1 | GYRASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-02-09 | — | — | US | disclosed |
| US-9481675-B2 | Gyrase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-11-01 | — | — | US | disclosed |
| US-20130079323-A1 | GYRASE INHIBITORS | TRIUS THERAPEUTICS, INC. (US) | 2013-03-28 | — | — | US | disclosed |
| EP-2475666-A2 | GYRASE INHIBITORS | Trius Therapeutics, Inc. (US) | 2012-07-18 | — | — | EP | disclosed |
| WO-2011032050-A2 | GYRASE INHIBITORS | TRIUS THERAPEUTICS, INC. (US) | 2011-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170037059-A1 | GYRASE INHIBITORS | TOP1, CA7, TOP2B | JAK3 4498/4885HPGDS 1772/4885CDC7 7/4885 |
| US-20130079323-A1 | GYRASE INHIBITORS | TOP1, CA7, TOP2B | JAK3 4498/4885HPGDS 1772/4885CDC7 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.